Technical Roundup on Services Stocks -- Booz Allen Hamilton, Qiagen, Myriad Genetics, and INC Research

Aug 02, 2016, 10:22 ET from Chelmsford Park SA

NEW YORK, August 2, 2016 /PRNewswire/ -- redirects investors' attention to the Services sector, which as per U.S. Census Bureau, primarily consists of truck transportation, messenger services and warehousing; information sector services; securities, commodities and other financial investment services; rental and leasing services; health care and social assistance; etc. In focus are the following equities ahead of today's trading session: Booz Allen Hamilton Holding Corp. (NYSE: BAH), Qiagen N.V. (NASDAQ: QGEN), Myriad Genetics Inc. (NASDAQ: MYGN), and INC Research Holdings Inc. (NASDAQ: INCR). Sign up today and download for free the research reports for the stocks covered today at:

Booz Allen Hamilton Holding  

McLean, Virginia headquartered Booz Allen Hamilton Holding Corp.'s stock finished Monday's session 0.39% lower at $30.76. A total volume of 860,046 shares was traded. The Company's shares have gained 3.78% in the past month, 11.90% over the previous three months, and 0.78% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 3.92% and 6.84%, respectively. Additionally, shares of Booz Allen Hamilton Holding, which provides management and technology, consulting, and engineering services to governments, corporations, and not-for-profit organizations in the U.S. and internationally, have a Relative Strength Index (RSI) of 55.01.

On July 13th, 2016, General Services Administration (GSA)/Federal System Integration and Management Center (FEDSIM) awarded Booz Allen Hamilton a seat on the $460 million USCYBERCOM MA Indefinite Delivery, Indefinite Quantity contract. Booz Allen will provide mission support services that include providing capabilities and expertise in the full range of technologies, Cyberspace Operations, joint operation planning, training and exercises. This award builds on Booz Allen's existing relationship with the United States Cyber Command as the firm continues to be one of the premier providers of cyber security capabilities for the Department of Defense. BAH complete research report is just a click away at:


On Monday, shares in Venlo, the Netherlands headquartered Qiagen N.V. ended the session flat at $26.80. The stock recorded a trading volume of 1.31 million shares, which was higher than its three months average volume of 1.13 million shares. The Company's shares have surged 22.88% in the last one month and 19.01% in the previous three months. The stock is trading 22.10% above its 50-day moving average and 15.25% above its 200-day moving average. Moreover, shares of Qiagen, which provides sample to insight solutions that transform biological samples into valuable molecular insights worldwide, have an RSI of 82.69.

On July 28th, 2016, QIAGEN reported net sales of $334.4 million and EPS of $0.09 in Q2 2016. The company also announced new plans to return $300 million of capital to shareholders by the end of 2017.

On August 1st 2016, research firm HSBC Securities upgraded the Company's stock rating from 'Hold' to 'Buy'. The complimentary report on QGEN can be downloaded at:

Myriad Genetics  

Salt Lake City, Utah headquartered Myriad Genetics Inc.'s stock rose 1.61%, closing the session at $31.48 with a total volume of 829,313 shares traded. The Company's shares have gained 2.88% in the last one month. The stock is trading 1.82% below its 50-day moving average. Additionally, shares of Myriad Genetics, which focuses on the development and marketing of predictive, personalized, and prognostic medicine tests worldwide, have an RSI of 45.53.

On July 11th, 2016, Myriad Genetics, in collaboration with researchers from the Institute of Cancer Research in London, announced positive results for EndoPredict®, a second-generation prognostic gene expression test for breast cancer. The study achieved its primary endpoint by demonstrating that EndoPredict (EPclin) was superior to the first-generation Oncotype DX Breast Recurrence Score® (RS) in predicting the long-term recurrence of ER+, HER2- primary breast cancer.

On July 29th, 2016, research firm Bank of America/ Merrill downgraded the Company's stock rating from 'Neutral' to 'Underperform'. Sign up for your complimentary report on MYGN at:

INC Research Holdings  

On Monday, shares in Raleigh, North Carolina headquartered INC Research Holdings Inc. recorded a trading volume of 4.26 million shares, which was above their three months average volume of 855,250 shares. The stock ended the day 3.93% lower at $42.76. The Company's shares have advanced 12.14% in the past month. The stock is trading above its 50-day moving average by 3.25%. Furthermore, shares INC Research Holdings, which provides various clinical development services for the biopharmaceutical and medical device industries, have an RSI of 53.23.

On July 28th, 2016, INC Research Holdings reported that its net service revenue for the three months ended June 30th, 2016 increased by 13.8% to $258.8 million compared to net service revenue of $227.4 million for the three months ended June 30th, 2015. The Company's net income for the three months ended June 30th, 2016 was $30.4 million, resulting in diluted earnings per share of $0.54, compared to net income of $23.3 million, or $0.39 per diluted share, for the three months ended June 30th, 2015. Download the research report for free on INCR at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA